Halozyme – HyQvia Approval in EU and Upcoming milestones = Upside
Approval of HyQvia (L, 10% Gammagard liquid + rHuPH20, partnered with Baxter for primary immunodeficiencies, PI) in Europe increases the probability of approval of Herceptin SC and MabThera SC in 2Q13 and YE13 respectively. Clarity on the timelines of approval of HyQvia SC in US is expected this quarter. HYLENEX (L, rHuPH20, adjuvant to increase the absorption and dispersion of other injected drugs) has gained 50% of market share in 16 months of launch showing acceptability of Halozyme’s (HALO) ENHANZE platform (recombinant human hyaluronidase, rHuPH20 use in the delivery of biologics- switching from IV injections to SC). Data from PEGPH20 in pancreatic cancer (ASCO 2013) boosted the stock and we expect further upside from... For more detail, please read our report released on May 24, 2013, titled, “HyQvia Approval in EU and Upcoming milestones = Upside”.
More Publications
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
US$ 2,500.00
January 2014
145 pages
THERAPEUTIC CLASS REPORT: WILL NEXT GENERATION ORAL ANTICOAGULANTS REPLACE WARFARIN AS MAINSTAY THERAPY
US$ 2,000.00
August 2011
100 pages
Psoriasis: Oral and Novel Biologics to Change Future Market Dynamic
US$ 3,000.00
April 2012
56 pages
Stroke Prevention in Atrial Fibrillation - View on Upcoming Milestones
US$ 90.00
August 2011
2 pages
Halozyme – “HyQvia’s Delay – Percolation to Other Drugs in the Pipeline?”
US$ 140.00
May 2012
6 pages
